BMS pays $23M for ADC work

Today's Big News

Apr 20, 2023

Promore's scar trial leaves deep wound as phase 2 fail sends stock spiraling down


Abdera skyrockets out of stealth with $142M as radiopharmaceutical ambitions take flight


Bristol Myers pays $23M to develop solid tumor ADCs based on Tubulis' toxicity-taming technology


Fierce Biotech Fundraising Tracker '23: Abdera unveils with $142M; Enveda tacks on $51M

 

Featured

Promore's scar trial leaves deep wound as phase 2 fail sends stock spiraling down

The nine-year wait for new clinical data on Promore Pharma’s ensereptide has ended in disaster, with the failure of the polypeptide to reduce scarring in a midphase trial wounding the biotech’s share price.
 

Top Stories

Abdera skyrockets out of stealth with $142M as radiopharmaceutical ambitions take flight

Abdera is unveiling with $142 million in combined series A and B cash to build out a new wave of radiopharmaceuticals. The biotech is planning to ask the FDA to enter clinical trials with a lead asset in 2024.

Bristol Myers pays $23M to develop solid tumor ADCs based on Tubulis' toxicity-taming technology

Bristol Myers Squibb is getting deeper into antibody-drug conjugates, paying Tubulis $22.8 million upfront to access technology designed to create more stable drugs with improved risk-benefit profiles.

Minimizing Barriers to eConsent Adoption

Michael Hughes, Chief Product Officer at YPrime discusses the benefits and challenges of eConsent implementation and how to circumvent the biggest barriers to adoption.

Fierce Biotech Fundraising Tracker '23: Abdera unveils with $142M; Enveda tacks on $51M

Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing.

What spurred Lilly, Novo and Sanofi to slash insulin prices? Expert gives her take

Not one, not two, but three of the industry's top diabetes players last month slashed prices on their competing insulins. After Eli Lilly's move, the strategy was quickly picked up by Novo Nordisk and Sanofi, drawing praise from lawmakers and advocacy groups alike. So, what was behind the sudden change?

Fresenius Kabi recalls newly acquired infusion pump over possible leaks

Less than a year after putting down $240 million to acquire Ivenix and its sensor- and software-backed infusion pump, Fresenius Kabi is recalling more than 1,500 of the systems.

Veeva study cites timely data entry, quality as biggest medtech trial challenges

A recent study conducted by cloud healthcare software provider Veeva says on-time data entry and data quality are the top challenges for medtech companies working with clinical research sites.

Intuitive sees robotic surgeries skyrocket in Q1 as procedures inch toward pre-pandemic norms

True to its namesake, Intuitive Surgical’s da Vinci robotic surgery system has become increasingly prolific amid the current renaissance period—as in, the resurgence of regular healthcare procedures as the COVID-19 pandemic transitions into an endemic.

HIMSS23: Epic analytics leader details efforts to bring GPT-4 into healthcare and growing work in genomics, life sciences

CHICAGO—Epic’s Phil Lindemann chatted on the show floor at the HIMSS 2023 conference about the EHR giant's work to integrate GPT-4 into its EHR and is expanding work in genomics and life sciences.
 
Fierce podcasts

Don't miss an episode

'The Top Line': The biotechs that scored top VC dollars in 2022, plus this week's headlines

This week on "The Top Line," we talk about biotech’s top money raisers in 2022. We also cover J&J's talc litigation, prison plans for Elizabeth Holmes and more of this week's top headlines.
 

Resources

Research

Maximizing Clinical Trial Success

Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies
Whitepaper

eConsent: Flexible Consent Through Enabling Technologies

How can eConsent provide a more flexible approach to informed consent?

Whitepaper

The Hematopoietic Colony Forming Cell (CFC) Assay for Drug Safety and Toxicity

The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process

Whitepaper

Accessing and Analyzing Relevant Content in Today’s Information Chaos – R&D Challenges and Opportunities

We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing?

Whitepaper

Blueprint for Commercializing Cell and Gene Therapies

How advanced medicines commercial readiness differs and the resources needed to maximize potential.

Whitepaper

Coming to America: Keys to Success for ex-US Digital Health Companies Entering the US Market

This paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market.
Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.

Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
 

Industry Events

 

Upcoming Fierce Events

1-3
May
May 1-3, 2023 | Jersey City, NJ
12-14
Jun
San Diego, CA
13
Jun
Free Virtual Event
20-22
Jun
Free Virtual Event
22
Jun
Free Virtual Event

View all events